In this study, a new series of fourteen 2-amine-5-arylideneimidazolones (7–20), representing two different topologies (A and B), as potential inhibitors of the main cancer MDR protein, i.e., ABCB1 efflux pump, was investigated. Here, ABCB1 is linked to cancer.